Year on Year Advice

Molecular biology of cancer sign and the ER-axis may also explain another puzzling clinical observation. During the first 15 years of tamoxifen use, most clinicians assumed that long-term administration should be more effective compared to shorter courses. Indeed, prospective randomized trials and a worldwide overview of clinical results in cancer treatment centers have demonstrated that while 1 year of adjuvant tamoxifen improves disease-free and overall survival, 2 years and 5 years provide even more benefit. However, in two prospective trials in which women who reached 5 years on adjuvant tamoxifen were randomly assigned to ongoing maintenance versus discontinuation of the drug, there was no apparent benefit to more than 5 years; there may actually be a higher risk of recurrence and death. Recent in vitro studies have demonstrated that, as in bone and liver, tamoxifen can behave in an agonistic manner for the ER in inflammatory breast cancer tissue, perhaps due to a change in the balance of ERa and ERb, as well as coactivators and

Breast Cancer Therapy As Well As Medication